These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17083268)

  • 21. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
    Ferrario C
    Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
    Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
    Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
    Chrysant SG; Weber MA; Wang AC; Hinman DJ
    Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of olmesartan medoxomil in the management of hypertension.
    Unger T; McInnes GT; Neutel JM; Böhm M
    Drugs; 2004; 64(24):2731-9. PubMed ID: 15563246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
    Yokoyama H; Averill DB; Brosnihan KB; Smith RD; Schiffrin EL; Ferrario CM
    Am J Hypertens; 2005 Jul; 18(7):922-9. PubMed ID: 16053988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.
    Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Waki H; Maeda M; Ogawa H; Kim-Mitsuyama S
    Atherosclerosis; 2014 Sep; 236(1):101-7. PubMed ID: 25016364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
    Ichikawa S; Takayama Y
    Hypertens Res; 2001 Nov; 24(6):641-6. PubMed ID: 11768722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan.
    Saito I; Kushiro T; Hirata K; Sato Y; Kobayashi F; Sagawa K; Hiramatsu K; Komiya M
    J Clin Hypertens (Greenwich); 2008 Apr; 10(4):272-9. PubMed ID: 18401224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early antihypertensive efficacy of olmesartan medoxomil.
    Saito I; Kushiro T; Ishikawa M; Matsushita Y; Sagawa K; Hiramatsu K; Komiya M
    J Clin Hypertens (Greenwich); 2008 Dec; 10(12):930-5. PubMed ID: 19120719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and tolerability of olmesartan.
    Brunner HR
    Clin Ther; 2004; 26 Suppl A():A28-32. PubMed ID: 15291377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
    Brunner HR; Arakawa K
    Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus].
    Lancellotti P
    Rev Med Liege; 2007 Mar; 62(3):175-9. PubMed ID: 17511387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):887-95. PubMed ID: 19673666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
    Nussberger J; Koike H
    Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
    Fliser D; Buchholz K; Haller H;
    Circulation; 2004 Aug; 110(9):1103-7. PubMed ID: 15313950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
    Sezai A; Soma M; Hata M; Yoshitake I; Unosawa S; Wakui S; Shiono M
    Ann Thorac Cardiovasc Surg; 2011; 17(5):487-93. PubMed ID: 21881353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system.
    Resnick LM; Catanzaro D; Sealey JE; Laragh JH
    Am J Hypertens; 2004 Mar; 17(3):203-8. PubMed ID: 15001191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
    Rosenbaum D; Girerd X
    Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olmesartan medoxomil: in children and adolescents with hypertension.
    Muir VJ; Keating GM
    Drugs; 2010 Dec; 70(18):2439-47. PubMed ID: 21142262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.
    Brunner HR; Nussberger J
    J Hypertens Suppl; 2001 Jun; 19(1):S15-20. PubMed ID: 11451210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.